

A Fungus Among Us

Theodore Wright, MD May 8, 2018




Plan

- What is a fungus?
- Which fungi do we really care about and why?
 - Target Candida
- Diagnosis
- Treatment
- Next week is stewardship in antifungals



A Fungus Among Us



I cannot forecast to you the action of fungual to is a riddle wrapped in a mystery installation.


Russian national interest.


(Winston Churchill)


izquotes.com



What is a Fungus?

















How science orders Fungi








Basidiomycota

- Cryptococcus
- Mushrooms

Many more














Ascomycota

- Candida
- Aspergillus
- Blastomyces
- Histoplasma
- Coccidioides
- Paracoccioides
- Penicillium
- Sporothrix
- Fusarium
- Scedosporium











Zygomycota






- Mucor & Rhizopus
- Fast growing
- Sporangia





How we order Fungi





A Fun Guy

- Cell membrane:
 - Ergosterol (fungi version of cholesterol).
 - Amphotericin, echinocandins, azoles.

 Cell Wall: Surrounds the membrane. Contains Chitin.



Treatment

Class	Mechanism
Polyenes Amphotericin B & Nystatin	Disrupt fungal membrane by binding to ergosterol
<u>Azoles</u> Vori, fluc, posa, isavu, keto	Inhibit synthesis of ergosterol
Nucleoside analogue 5-FU	Inhibit DNA and RNA synthesis
Allylamines Terbinafine	Inhibit ergosterol synthesis
<u>Grisans</u> Griseofulvin	Inhibit fungal mitosis
<u>Candins</u> Micafungin	Inhibit cell wall synthesis



Amphotericin B

- Ampho B deoxycholate data
- Liposomal Ampho B Tx .
- Nephrotoxicity
 - 50% of patients develop AKI on Ampho B.
 - Liposomal formulations much lower rates of AKI.



Fluc, Itra, Posa, Isavu

- C. Krusei and C. glabrata??
- P450 inhibition Interactions.
- Fluconazole:
 - 90% oral bioavailability and 70% penetrates the CSF.
 Concentrates in urine.
- Voriconazole
 - Better for C Krusei and glabrata.
 - Hepatic, CNS, and visual toxicity.
- Posa and isavu
 - Not used as primary tx for candidiasis.



EchinoCANDIDAns

 Caspofungin, micafungin, anidulafungin.

First line treatment for candidemia.



 Low MICs for most candida species.



Flucytosine

No effect on C Krusei.

High CNS penetration and eye penetration.

 CNS infections and endocarditis. Always used in conjunction with another antifungal.






Candida Sp	Fluc	Itra	Vori	Posa	5-FU	Ampho	Candins
Albicans	S	S	S	S	S	S	S
Tropicalis	S	S	S	S	S	S	S
Parapsilosis	S	S	S	S	S	S	S or R?
Glabrata	S-DD to R	S-DD to R	S-DD to R	S-DD to R	S	S to I	S
Krusei	R	S-DD to R	S	S	I to R	S to I	S
Lusitaniae	S	S	S	S	S	S	S to R



Favorite Fun Guy?





Candida: A Fun Guy

- Any organ system.
- >90% of invasive disease is due to C. albicans, glabrata, krusei, parapsilolsis, tropicalis.

 ~50% of invasive disease is due to non-albicans candida.

47% mortality with candidemia.



Diagnosis

Which of these tests is available at your facility?

A. Culture and stain

B. PCR

C. Ab testing

D. Beta-D-glucan testing (Fungitell)



Diagnosis

Culture and Stain = Gold Standard

- Ag, Ab, and PCR still establishing a role.
- Beta-D-glucan, AKA fungitell:
- PCR Similar issues as fungitell.





What do I do with those positive culture results?



When to Treat?

- A. Candida in sputum cx.
- B. Candida in urine cx of an asymptomatic nonneutropenic patient.
- C. Candida from a wound culture
- D. Candida from a ETT aspirate of an intubated patient.
- E. Candida from the blood.
- F. D and E
- G. All of the above




Top three myths of fungal infections...

- 1. My patient has Candida pneumonia
- 2. My patients has Candida UTI

3. Fungi are simple.



Candida Pneumonia ??



Colonizer 22% of healthcare workers & 55% of inpatients on abx will grow candida from their sputum. PPV with candida is 42% and on BAL its 29%.

Masur, H; et al. Pulmonary Disease Caused By Candida Species. The American Journal of Medicine. The American Journal of Medicine. 1977.

Andes; et al. Pulmonary Candidiasis in Patients with Cancer. CID. 2012:54.

Candida Pneumonia??

- 301 patients who died of pneumonia in ICU 77% had autopsy and 0% had histologically proven candida pneumonia. 44% had candida in sputum samples.
 - Albicans > glabrata > Tropicalis > Parapsilosis > Krusei.
- No correlation between amount of growth or number of sites colonized and propensity to develop invasive candidiasis.



Candida Pneumonia?

24% of ICU physicians would treat candidiasis in an intubated and immunocompetent patient.



Candida Pneumonia !!!

- True candida pneumonia is via candidemia with hematogenous spread.
 - Candida pneumonia without disseminated candida occurred in less than 1% of cases.
- Do not treat candida in sputum.

 Do treat disseminated candidemia presenting with hematogenous spread of candida to the lungs.



Candida Pneumonia


In an immunosuppressed patient with candidemia and Candida on a BAL which tx would you initiate?

- A. Micafungin
- B. Amphotericin B deoxycholate
- C. Liposomal Ampho B
- D. Isavuconazole
- E. Fluconazole
- F. Voriconazole




Candida UTI?





Candiduria



- Third most common nosocomial urine isolate in Europe.
 - After E Coli and Enterococcus.
- Candiduria == Candidemia or cystitis
- When to tx asymptomatic candiduria?
 - Very low birth weight infants
 - Neutropenic patients
 - Impending urologic procedures.

Treat these patients with candiduria.



Symptomatic Candiduria

- Hematogenous
 - Renal abscesses presenting with flank pain.
- Ascending
 - DM, female, foley catheter, and anatomic abnormalities.
 - Indolent. Often leads to pyelo or renal fungal ball before being discovered.
 - Change the foley, tx their diabetes, fix their GU reflux.



Candiduria Treatment

- A gentleman is having lithotripsy for a persistent nephrolithiasis and has candida albicans growing from a recent urine cx. Which would you treat him with?
- A. Micafungin
- B. Amphotericin B
- C. Liposomal Amphotericin B
- D. Voriconazole
- E. Fluconazole
- F. Caspofungin



Candidemia

4th most common nosocomial cause of BSI.


- Rising prevalence of C. glabrata BSI.
- Neutropenic v non-neutropenic candidemia

- Prefer echinocandins but no head to head data to say it's outcomes are superior.
 - Safety profile and efficacy.



Non-Neutropenic Candidemia


- Think CVC!
 - 70% of non-neutropenic patients with candidemia have a CVC.
- DM, immunosuppression and TPN.
- Echinocandin, fluconazole, IV or PO, is acceptable alternative or step down.
- Get sensitivities.
- In 5-7 days de-escalate from echinocandin to fluconazole.
- Blood cx QD or QOD until cleared.
- Tx for 2 weeks.





Neutropenic Candidemia

- Think gut source.
- Echinocandin still first line.



- CVC removal on case by case basis.
- Otherwise treat as for non-neutropenic candidemia



Candida Endocarditis

- Native valve endocarditis:
 - Liposomal Ampho B +/- 5-FU or high dose echinocandin (micafungin 150 mcg daily).
 - Stepdown to fluc 400 mg daily
 - Valve replacement!
 - If unable to undergo valve replacement then chronic suppressive fluc.
- Prosthetic Valve
 - Same recs.





References

- Meersseman et al. Significance of the Isolation of Candida from airway samples in critically ill patients. Intensive Care Med. 2009. Vol 35.
- Haron et al. Primary Candida Pneumonia. Medicine. 1993. 72(3).
- Meersseman et al. Significance of the Isolation of Candida from airway samples in critically ill patients. Intensive Care Med. 2009. Vol 35.
- https://en.wikipedia.org/wiki/Taxonomic_rank
- https://en.wikipedia.org/wiki/Zygomycota
- Masur, H; et al. Pulmonary Disease Caused By Candida Species. The American Journal of Medicine. The American Journal of Medicine. 1977.
- Andes; et al. Pulmonary Candidiasis in Patients with Cancer. CID. 2012:54.
- Kontoniyanis; et al. Pulmonary Candidasis in Patients with Cancer. CID. 2002. 34: 400-3.
- Bouza E; et al. A European Perspective on nosocomial UTI. Clinical Microbiol Infect. 2001

